ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 703,45
0,33%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AnaptysBio Inc (ANAB)

  7. AnaptysBio Inc (ANAB) Actualités

ANAB AnaptysBio Inc

23,94
0,29 (1,23%)
31 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AnaptysBio Inc ANAB NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,29 1,23% 23,94 22:00:17
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
23,80 23,66 24,82 23,94 23,65
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/5/202422:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:20EDGAR2Form 8-K - Current report
09/5/202422:15GLOBEAnaptys Announces First Quarter 2024 Financial Results and..
09/5/202422:10GLOBEAnaptys Announces Positive Top-Line GEMINI-2 Phase 3..
09/5/202422:05GLOBEAnaptys to Receive $50 Million in a Capped Non-Recourse..
06/5/202418:59EDGAR2Form SC 13G - Statement of acquisition of beneficial..
24/4/202415:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
11/3/202421:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:19EDGAR2Form 8-K - Current report
29/2/202415:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
14/2/202416:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202415:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
10/1/202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:09EDGAR2Form 8-K - Current report
27/11/202322:17EDGAR2Form 8-K - Current report
27/11/202322:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
07/11/202322:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
02/11/202321:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:18EDGAR2Form 8-K - Current report
02/11/202321:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
01/11/202314:15GLOBEAnaptys Announces Participation in November Investor..
25/10/202322:43EDGAR2Form 8-K - Current report
11/10/202315:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
10/10/202315:01EDGAR2Form 8-K - Current report
09/10/202314:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09/10/202314:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09/10/202314:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
19/9/202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202300:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/9/202322:18EDGAR2Form 8-K - Current report
18/9/202322:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12/9/202315:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
07/8/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:18EDGAR2Form 8-K - Current report
07/8/202322:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
31/7/202320:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
31/7/202319:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..

Dernières Valeurs Consultées

NASDAQ
ANAB
AnaptysBio
LSE
49DS
Mound Fin.4 4cs
LSE
47QR
Hsbc Bk. 2040
EU
3PLT
Leverage
COIN
CCCCETH
CryptoCart
EU
BTGC7
TAGUS Sociedade de Titul...
AMEX
BMAR
Innovator US Equity Buff...
BIT
UC4YAH
Unicredit Bank
NASDAQ
LFTRW
Lefteris Acquisition
BIT
UB3CV6
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés